SERINC3 (Serine incorporator 3) is a multi-pass transmembrane protein belonging to the SERINC family, which is implicated in lipid metabolism, membrane remodeling, and cellular defense mechanisms. Primarily localized to the plasma membrane and intracellular organelles, SERINC3 is involved in incorporating serine into phosphatidylserine and sphingolipids, playing roles in membrane structure and signaling. Recent studies highlight its antiviral activity, particularly in restricting HIV-1 infectivity by impairing viral fusion, though its potency is weaker compared to SERINC5. SERINC3 antibodies are essential tools for detecting and studying the protein’s expression, post-translational modifications, and interactions in various biological contexts.
These antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate SERINC3’s tissue distribution, subcellular localization, and dysregulation in diseases. Research links altered SERINC3 expression to cancers, neurological disorders, and immune dysfunctions, making it a potential biomarker or therapeutic target. Commercial SERINC3 antibodies are typically raised in rabbits or mice, with validation including knockout controls to confirm specificity. Challenges include cross-reactivity with other SERINC family members and variability between antibody clones. Ongoing studies aim to clarify SERINC3’s mechanistic roles in membrane biology and its interplay with viral or cellular factors, driving demand for reliable antibodies in both basic and translational research.